UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, zip code)
(Issuer’s telephone number)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On August 7, 2025, the following proposals were submitted to the stockholders of Apyx Medical Corporation (the “Company”) at its annual meeting of stockholders: (1) the election of five (5) directors; (2) the ratification of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025; (3) the approval of the a non-binding advisory resolution supporting the compensation of the Company’s named executive officers; (4) the approval of a non-binding advisory resolution supporting the frequency of an advisory vote on the compensation of the Company’s named executive officers; and (5) the approval of a resolution to amend the Company’s Certificate of Incorporation to remove Article EIGHTH and replace with “intentionally omitted.”
The proposals are described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on June 25, 2025.
The following are the final voting results for each proposal:
Proposal 1: |
The Company’s stockholders elected each of the following five (5) directors to serve on the Board of Directors of the Company until the 2026 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, by the following vote: |
| Name | Number of Votes Cast in Favor | Number of Votes Cast Against | Number of Votes Abstained | Broker Non-Votes | ||||
| Stavros G. Vizirgianakis | 19,107,606 | 105,624 | 37,917 | 6,772,342 | ||||
| Charles D. Goodwin | 18,943,570 | 249,305 | 58,272 | 6,772,342 | ||||
| Lawrence J. Waldman | 18,972,128 | 112,320 | 166,699 | 6,772,342 | ||||
| Minnie Baylor-Henry | 18,877,754 | 186,304 | 187,089 | 6,772,342 | ||||
| Wendy Levine | 18,931,749 | 132,382 | 187,016 | 6,772,342 |
Proposal 2: |
The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025, by the following vote: |
| Number of Votes Cast in Favor | Number of Votes Cast Against | Number of Votes Abstained | Broker Non-Votes | |||
| 25,930,634 | 25,032 | 67,823 | - |
Proposal 3: |
The Company’s stockholders approved of a non-binding advisory resolution supporting the compensation of the Company’s named executive officers, by the following vote: |
| Number of Votes Cast in Favor | Number of Votes Cast Against | Number of Votes Abstained | Broker Non-Votes | |||
| 18,963,101 | 182,700 | 105,346 | 6,772,342 |
| Proposal 4: | The Company’s stockholders approved the frequency of an advisory vote on the compensation of the named executive officers of the Company, by the following vote: |
| One Year | Two Years | Three Years | Number of Votes Abstained | Broker Non-Votes | ||||
| 9,205,086 | 25,369 | 7,530,910 | 2,489,782 | - |
|
Proposal 5: |
The Company’s stockholders approved the adoption of an amendment to the Company’s Certificate of Incorporation to delete the text of Article EIGHTH and replace with “intentionally omitted”, by the following vote: |
| Number of Votes Cast in Favor | Number of Votes Cast Against | Number of Votes Abstained | Broker Non-Votes | |||
| 19,047,016 | 99,065 | 105,066 | 6,772,342 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 13, 2025 |
Apyx Medical Corporation |
|
|
|
|
|
By: |
/s/ Matthew Hill |
|
|
Matthew Hill |
|
|
Chief Financial Officer, Secretary and Treasurer |